Abstract:Background: Propranolol, a nonselective β-blocker, has been reported as efficient for controlling the growth of complicated infantile hemangiomas (IHs). No uniformly accepted protocol exists regarding the administration of oral propranolol for IH. Objective: We sought to share our experience using propranolol for problematic IH and to evaluate the efficacy of this treatment modality. Methods: A retrospective chart review analysis was performed for 35 consecutive children treated with propranolol as an oral solution on an outpatient basis in our dermatology/vascular anomalies clinic. A protocol was established with the help of our pediatric cardiologists, including pretreatment electrocardiography and echocardiography. Medical photographs taken after 2 months of treatment were rated by two independent evaluators. Results: We treated 31 girls and 4 boys with a median age of 3.5 months. Rapid improvement was reported in the first days of treatment in 34 patients. Mean improvement after 2 months was 61.5%. No serious adverse effects were reported. Conclusion: Propranolol was effective in controlling the proliferative phase of problematic IH. It was well tolerated in our study. Outpatient treatment is possible if parents follow strict guidelines. Propranolol should be a first-line treatment for problematic IH in carefully selected patients. Renseignements de base: Le propranolol, un bêta-bloquant non sélectif, s'est révélé efficace pour maîtriser la croissance des hémangiomes infantiles compliqués. On ne dispose pas d'un protocole uniformément accepté quant à l'administration du propranolol oral contre l'hémangiome infantile. Objectif: Nous voulions faire part de notre expérience d'utilisation du propranolol pour traiter les hémangiomes infantiles problématiques et évaluer l'efficacité de cette modalité de traitement. Méthodes: On a exécuté une analyse rétrospective des dossiers de 35 enfants consécutifs qui ont été traités par une solution orale de propranolol de façon ambulatoire dans notre clinique de dermatologie/d'anomalies vasculaires. On a établi un protocole avec l'aide de nos cardiologues pédiatriques, lequel comprenait notamment un ECG et une échographie cardiaque avant le traitement. Les photographies médicales prises après 2 mois de traitement ont été évaluées par deux évaluateurs indépendants. Résultats: Nous avons traité 31 filles et 4 garçons dont l'âge médian était de 3,5 mois. On a signalé, chez 34 patients, une amélioration rapide dès les premiers jours de traitement. L'amélioration moyenne après deux mois s'élevait à 61,5 %. Aucun effet indésirable grave n'a été signalé. Conclusion: Le propranolol était efficace pour maîtriser la phase proliférative de l'hémangiome infantile problématique. Lors de notre étude, il a été bien toléré. Le traitement peut être administré de façon ambulatoire si les parents observent les directives à la lettre. Nous croyons qu'en présence d'un hémangiome infantile problématique, le traitement par le propranolol doit être administré en première intention à des patients soigneusement sélectionnés.

Safety of propranolol in neonates with severe infantile hemangiomas: A fourteen-year experience

Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review

Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital

Safety assessment of propranolol for infantile hemangioma: a study in an Asian population

Safety of Prior Propranolol Therapy for Infantile Hemangioma

Efficacy of propranolol for cutaneous hemangiomas in premature children

Propranolol in the Treatment of Problematic Infantile Hemangioma: Review of 35 Consecutive Patients from a Vascular Anomalies Clinic

Effectiveness of Propranolol in the Treatment of Infantile Hemangioma Beyond the Proliferation Phase

Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience

Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients

Safety of Propranolol for Severe Infantile Hemangioma: A Prospective Cohort Study

Efficacy and safety of atenolol versus propranolol for treatment of infantile haemangioma: A narrative review

[Rapid regression of infantile haemangioma with 2% propranolol ointment]

Cardiac Evaluation before and after Oral Propranolol Treatment for Infantile Hemangiomas

Oral propranolol for the treatment of hemangiomas in high-risk infants: safety and cost analysis of outpatient-initiated therapy

Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference

Mechanisms of propranolol action in infantile hemangioma

The efficacy and safety of treatments for infantile hemangiomas: a Bayesian network meta-analysis

Efficacy and Safety of Oral Propranolol or Topical Timolol for the Treatment of Superficial Infantile Hemangiomas